Dr. Jardine earned his undergraduate degree from the University of Washington and PhD from the Scripps Research Institute. During his training, he worked on HIV vaccine design where he pioneered the early efforts in germline-targeting. He received an HHMI/Helen Hay Whitney postdoctoral fellowship, where he worked to validate the candidate vaccine he created, eOD-GT8, in small animal models. In 2016, Dr. Jardine moved to Boston where he was the first scientist and Head of Antibody Discovery at the Institute for Protein Innovation, a newly formed nonprofit. There, he helped grow the institute and established a high throughput synthetic antibody discovery platform. In 2019, he returned to Scripps/IAVI as the Director of Product Discovery and Optimization. His group studies how the adaptive immune system response to antigens, specifically focusing on how broad recognition can be achieved across targets of high antigenic diversity.
